Amneal Pharmaceuticals (AMRX) Change in Account Payables (2017 - 2026)

Amneal Pharmaceuticals' Change in Account Payables history runs 10 years deep, the most recent figure standing at -$41.1 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 3556.76% year-over-year to -$41.1 million; the TTM figure through Mar 2026 stood at -$39.0 million (down 181.65% YoY), while the FY2025 annual figure was $931000.0, down 98.29% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$41.1 million, down from -$2.2 million in the prior quarter.
• The five-year high for Change in Account Payables was $34.1 million in Q4 2024, with the low at -$41.1 million in Q1 2026.
• The 5-year median for Change in Account Payables is $1.7 million (2023), against an average of $1.5 million.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables tumbled 6605.33% in 2022, then soared 1493.61% in 2023.
• Amneal Pharmaceuticals' Change in Account Payables stood at -$407000.0 in 2022, then jumped by 1493.61% to $5.7 million in 2023, then jumped by 501.23% to $34.1 million in 2024, then plunged by 106.38% to -$2.2 million in 2025, then sank by 1788.88% to -$41.1 million in 2026.
• Business Quant data shows AMRX's Change in Account Payables at -$41.1 million in Q1 2026, -$2.2 million in Q4 2025, and -$2.2 million in Q3 2025.